Finch Therapeutics Group, Inc. Common Stock
FNCH
FNCH was delisted on the 24th of May, 2024.
1 hedge funds and large institutions have $29.1K invested in Finch Therapeutics Group, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 10 closing their positions.
91% less funds holding
Funds holding: 11 → 1 (-10)
91% less capital invested
Capital invested by funds: $338K → $29.1K (-$309K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 10
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$155K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$94.3K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$18.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$10.8K |
| 5 |
BL
Bleichroeder LP
New York
|
-$2.52K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LSAG
1
Lake Street Advisors Group
Portsmouth,
New Hampshire
| $29.1K | – | – | – |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$155K | -59,028 | Closed |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| – | -$94.3K | -36,252 | Closed |
|
|
IC
4
Ikarian Capital
Dallas,
Texas
| – | -$18.1K | -6,892 | Closed |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| – | -$10.8K | -4,163 | Closed |
|
|
BL
6
Bleichroeder LP
New York
| – | -$2.52K | -971 | Closed |
|
7
BlackRock
New York
| – | -$850 | -327 | Closed |
|
8
Morgan Stanley
New York
| – | -$406 | -156 | Closed |
|
9
UBS Group
Zurich,
Switzerland
| – | -$286 | -110 | Closed |
|
10
Wells Fargo
San Francisco,
California
| – | -$18 | -7 | Closed |
|
FNCH Hedge Fund Activity: Q2 2024 in Review
1 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Finch Therapeutics Group, Inc. Common Stock (FNCH) for Q2 2024, worth a combined $29.1K — down 91% from $338K a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of FNCH and 0 opened new positions — a net loss of 10 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Susquehanna International Group, exiting entirely with an estimated $155K sold.
- 1 institutional investor held Finch Therapeutics Group, Inc. Common Stock (FNCH) as of Q2 2024, down from 11 in Q1 2024.
- Funds reported $29.1K of Finch Therapeutics Group, Inc. Common Stock stock for Q2 2024, down 91% quarter-over-quarter.
- 0 funds opened new Finch Therapeutics Group, Inc. Common Stock positions in Q2 2024 and 10 closed out, a net change of -10 holders.
- The largest Finch Therapeutics Group, Inc. Common Stock seller in Q2 2024 was Susquehanna International Group, an estimated $155K sold.
Based on aggregated 13F filings for Q2 2024.